Cytochalasin H isolated from mangrove-derived endophytic fungus inhibits epithelial-mesenchymal transition and cancer stemness

YAP/TAZ cancer stemness cytochalasin H (CyH) epithelial-mesenchymal transition (EMT) mangrove non-small cell lung cancer (NSCLC)

Journal

Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920

Informations de publication

Date de publication:
2021
Historique:
received: 09 07 2020
accepted: 01 12 2020
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 15 1 2021
Statut: epublish

Résumé

Our previous studies have isolated cytochalasin H (CyH) from endophytic fungus derived from mangrove and found that CyH induced apoptosis and inhibited migration and angiogenesis in non-small cell lung cancer (NSCLC) cells. In this study, we further investigated the effect of CyH on epithelial-mesenchymal transition (EMT) and cancer stemness of A549 and NCI-H460 NSCLC cells and the underlying mechanisms, especially the role of YAP/ TAZ signaling pathway in the process. Our results showed that CyH significantly inhibited invasive ability and the sphere formation of NSCLC cells. The expression of E-cadherin, an EMT epithelial marker, was obviously up-regulated, while the expression of Vimentin and N-cadherin, the EMT mesenchymal markers, was dramatically down-regulated by CyH treatment in NSCLC cells. Moreover, the expression of EMT-associated transcription factors including Slug, Twist1, and Snail1 and stemness markers including Nanog, Sox-2, and Oct-4 was significantly down-regulated by CyH treatment in NSCLC cells. Additionally, CyH significantly down-regulated YAP and TAZ expression and up-regulated LAST1/2 and MST1/2 expression, and CyH inhibited the interaction between YAP and TEAD. Furthermore, YAP knockdown abolished the effect of CyH on the expression of EMT- and stemness-related markers in NSCLC cells. Taken together, these results suggest that CyH inhibits EMT and cancer stemness of NSCLC cells

Identifiants

DOI: 10.7150/jca.50512 PMID: 33442415 PMC: PMC7797655
pubmed: 33442415
doi: 10.7150/jca.50512
pii: jcav12p1169
pmc: PMC7797655
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1169-1178

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Expert Opin Ther Pat. 2018 Dec;28(12):867-873
pubmed: 30482112
Mol Cells. 2018 Feb 28;41(2):83-92
pubmed: 29429151
Cancer Res. 2014 Aug 1;74(15):4170-82
pubmed: 24906622
Int J Clin Exp Pathol. 2020 Apr 01;13(4):701-710
pubmed: 32355518
Oncogene. 2015 Feb 5;34(6):681-90
pubmed: 24531710
Oncol Res. 2017 May 24;25(5):843-852
pubmed: 28508744
Nat Prod Rep. 2011 Jul;28(7):1208-28
pubmed: 21455524
J Med Chem. 2015 Jun 25;58(12):4857-73
pubmed: 25719868
J Thorac Oncol. 2012 Apr;7(4):723-30
pubmed: 22425921
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):E2441-50
pubmed: 22891335
Anticancer Agents Med Chem. 2015;15(3):327-35
pubmed: 25322987
Cancers (Basel). 2018 Apr 10;10(4):
pubmed: 29642615
J Cancer. 2019 May 12;10(9):1997-2005
pubmed: 31205560
Int J Cancer. 2018 Nov 1;143(9):2133-2144
pubmed: 29696628
Stem Cells. 2015 Jun;33(6):1705-18
pubmed: 25754111
Cancers (Basel). 2018 May 06;10(5):
pubmed: 29734788
Oncol Rep. 2018 Jun;39(6):2899-2905
pubmed: 29620283
Front Microbiol. 2018 Jan 05;8:2536
pubmed: 29354097
Asian Cardiovasc Thorac Ann. 2017 Nov;25(9):623-629
pubmed: 29058973
Cell. 2011 Nov 11;147(4):759-72
pubmed: 22078877
Annu Rev Pathol. 2018 Jan 24;13:395-412
pubmed: 29414248
J Cell Mol Med. 2013 Jan;17(1):30-54
pubmed: 23301832
J Cancer. 2018 Sep 8;9(19):3456-3466
pubmed: 30310502
Cancer Manag Res. 2019 Jul 08;11:6245-6252
pubmed: 31360073
Dev Dyn. 2018 Mar;247(3):462-472
pubmed: 28960588
J Fungi (Basel). 2018 Aug 24;4(3):
pubmed: 30149584
BMC Cancer. 2019 Jul 11;19(1):680
pubmed: 31296175
Fitoterapia. 2019 Sep;137:104278
pubmed: 31351910
PLoS One. 2014 Feb 06;9(2):e87893
pubmed: 24516569
Theranostics. 2020 Feb 18;10(8):3622-3635
pubmed: 32206112
Clin Transl Oncol. 2020 Mar;22(3):381-391
pubmed: 31134511
Clin Lung Cancer. 2019 Jul;20(4):e504-e513
pubmed: 31103348
Mol Cancer. 2018 Sep 3;17(1):134
pubmed: 30176928
Mol Cell Biol. 2008 Apr;28(7):2426-36
pubmed: 18227151
Cancer Res. 2014 Mar 1;74(5):1566-75
pubmed: 24413534
Cell J. 2019 Apr;21(1):62-69
pubmed: 30507090
J Nat Prod. 2019 Jul 26;82(7):1752-1758
pubmed: 31251621
Biol Pharm Bull. 2015;38(6):909-12
pubmed: 26027832

Auteurs

Zihan Xiu (Z)

Collaborative innovation center for antitumor active substance research and development, Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang 524023, P.R. China.

Jiao Liu (J)

Collaborative innovation center for antitumor active substance research and development, Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang 524023, P.R. China.

Xin Wu (X)

Guangdong Key Laboratory for Research and Development of Natural Drugs, Marine Medical Research Institute of Guangdong Zhanjiang, Department of Pharmacology, Guangdong Medical University, Zhanjiang 524023, P.R. China.
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang 524023, P.R. China.

Xiangyong Li (X)

Collaborative innovation center for antitumor active substance research and development, Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang 524023, P.R. China.

Sanzhong Li (S)

Collaborative innovation center for antitumor active substance research and development, Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang 524023, P.R. China.

Xiaofeng Wu (X)

Collaborative innovation center for antitumor active substance research and development, Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang 524023, P.R. China.

Xiaohua Lv (X)

Guangdong Key Laboratory for Research and Development of Natural Drugs, Marine Medical Research Institute of Guangdong Zhanjiang, Department of Pharmacology, Guangdong Medical University, Zhanjiang 524023, P.R. China.

Hua Ye (H)

Guangdong Key Laboratory for Research and Development of Natural Drugs, Marine Medical Research Institute of Guangdong Zhanjiang, Department of Pharmacology, Guangdong Medical University, Zhanjiang 524023, P.R. China.
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang 524023, P.R. China.

Xudong Tang (X)

Collaborative innovation center for antitumor active substance research and development, Institute of Biochemistry and Molecular Biology, Guangdong Medical University, Zhanjiang 524023, P.R. China.
Guangdong Key Laboratory for Research and Development of Natural Drugs, Marine Medical Research Institute of Guangdong Zhanjiang, Department of Pharmacology, Guangdong Medical University, Zhanjiang 524023, P.R. China.
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang 524023, P.R. China.
Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan 523808, P.R. China.

Classifications MeSH